This might in principle be successful, as has been demonstrated by our recent observation that clinical benefit can be achieved in an animal model for MS by sealing BBB tight junctions through the ectopic expression of the tight-junctional protein claudin-1 in BBB endothelium (Pfeiffer et al. 2011). Here, CLDN1 is linked to myeloid sarcoma.